These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29705836)

  • 1. Commentary on: A cost-effectiveness analysis of onabotulinumtoxin A as first-line treatment for overactive bladder.
    Abdelrahman A
    Int Urogynecol J; 2018 Aug; 29(8):1221. PubMed ID: 29705836
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of novel therapies for overactive bladder.
    Mayr CA; Shepherd JP
    Expert Rev Pharmacoecon Outcomes Res; 2014 Aug; 14(4):527-35. PubMed ID: 24809616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of botulinum toxin type A in non-neurogenic overactive bladder. Recommendations of the Working Group Urological Functional Diagnostics and Urology in Women].
    Bauer RM; Seif C; Bschleipfer T; Reitz A; Schultz-Lampel D;
    Urologe A; 2015 Mar; 54(3):368-72. PubMed ID: 25391442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Idiopathic overactive bladder: What to do in case of anticholinergic failure?].
    Boudy AS; Thubert T
    Prog Urol; 2015 Jun; 25(8):497-8. PubMed ID: 25748787
    [No Abstract]   [Full Text] [Related]  

  • 5. Onabotulinumtoxin A for idiopathic overactive bladder: raising the bar.
    Bauer RM; Gratzke C
    Eur Urol; 2012 Jul; 62(1):158-9. PubMed ID: 22537795
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacotherapy for overactive bladder: minimally invasive treatment -- botulinum toxins.
    Apostolidis A
    Expert Opin Pharmacother; 2011 May; 12(7):1029-39. PubMed ID: 21288184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective.
    Angulo JC; Sánchez-Ballester F; Peral C; Rejas J; Ramos J; Snedecor SJ; Sudharshan L; Liu S; Luo X
    Actas Urol Esp; 2016 Oct; 40(8):513-22. PubMed ID: 26988624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales.
    Freemantle N; Khalaf K; Loveman C; Stanisic S; Gultyaev D; Lister J; Drake M
    Eur J Health Econ; 2016 Sep; 17(7):911-21. PubMed ID: 26482712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neurogenic detrusor overactivity and onabotulinumtoxin A (Botox
    Kaufmann A
    Urologe A; 2017 Feb; 56(2):241-242. PubMed ID: 28070606
    [No Abstract]   [Full Text] [Related]  

  • 10. [Botulinum toxin injection for refractory non-neurogenic overactive bladder. Systematic review].
    Henriet B; Roumeguère T
    Rev Med Brux; 2015; 36(1):29-37. PubMed ID: 25856969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life clinical practice of onabotulinum toxin A intravesical injections for overactive bladder wet: an Italian consensus statement.
    Giannantoni A; Carbone A; Carone R; Cervigni M; Del Popolo G; Agrò EF; Giocoli Nacci G; Palleschi G; Salvatore S; Spinelli M; Tubaro A
    World J Urol; 2017 Feb; 35(2):299-306. PubMed ID: 27229889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of available therapies in the management of idiopathic overactive bladder: A systematic review of the literature].
    Moyson J; Legrand F; Vanden Bossche M; Quackels T; Roumeguère T
    Prog Urol; 2017 Mar; 27(4):203-228. PubMed ID: 28228331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial.
    Chuang YC; Kaufmann JH; Chancellor DD; Chancellor MB; Kuo HC
    J Urol; 2014 Dec; 192(6):1743-9. PubMed ID: 25046622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder.
    Leong RK; de Wachter SG; Joore MA; van Kerrebroeck PE
    BJU Int; 2011 Aug; 108(4):558-64. PubMed ID: 21166750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacoeconomic analysis of using mirabegron to treat overactive bladder in the setting of the Russian Federation health care].
    Kolbin AS; Vilyum IA; Proskurin MA; Balykina YE
    Urologiia; 2016 Feb; (1):32-39. PubMed ID: 28247701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
    Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
    Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum neurotoxin A for overactive bladder treatment: advantages and pitfalls.
    Chibelean C; Nechifor-Boila IA
    Can J Urol; 2015 Apr; 22(2):7681-9. PubMed ID: 25891330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin--a new therapeutic agent in girls with non-neurogenic overactive bladder--a case report and review of the literature.
    Kulik-Rechberger B; Piechuta L; Miotła P; Skorupski P; Rechberger T
    Ginekol Pol; 2010 Nov; 81(11):870-3. PubMed ID: 21361152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Botulinum toxin A for the Treatment of Overactive Bladder.
    Hsieh PF; Chiu HC; Chen KC; Chang CH; Chou EC
    Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26938559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of pharmacological treatments for overactive bladder from the perspective of the UK National Health Service.
    Nazir J; Posnett J; Walker A; Odeyemi IA; Hakimi Z; Garnham A
    J Med Econ; 2015 May; 18(5):390-7. PubMed ID: 25488631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.